trending Market Intelligence /marketintelligence/en/news-insights/trending/hcffqoipqb2yxmurzdectg2 content esgSubNav
In This List

Fennec's ear damage prevention drug gets US FDA fast track status

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Fennec's ear damage prevention drug gets US FDA fast track status

The U.S. Food and Drug Administration granted the fast-track designation to Fennec Pharmaceuticals Inc.'s Pedmark to prevent ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma.

Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The fast track designation allows the FDA to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.